Pfizer Inc. (NYSE:PFE) Shares Acquired by Bell Bank

Bell Bank boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 18.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,802 shares of the biopharmaceutical company's stock after buying an additional 52,771 shares during the quarter. Pfizer makes up approximately 0.7% of Bell Bank's portfolio, making the stock its 25th biggest position. Bell Bank's holdings in Pfizer were worth $8,803,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wells Trecaso Financial Group LLC increased its position in shares of Pfizer by 2.5% during the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock valued at $416,000 after acquiring an additional 350 shares during the last quarter. Washington Trust Advisors Inc. increased its holdings in Pfizer by 0.7% in the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company's stock valued at $1,424,000 after purchasing an additional 360 shares during the last quarter. PSI Advisors LLC lifted its stake in Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock worth $738,000 after purchasing an additional 385 shares in the last quarter. Western Pacific Wealth Management LP boosted its position in shares of Pfizer by 10.5% during the third quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 386 shares during the period. Finally, Waddell & Associates LLC raised its holdings in shares of Pfizer by 1.6% in the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock valued at $723,000 after buying an additional 388 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

Pfizer Stock Up 1.6 %

PFE stock traded up $0.42 during trading on Friday, hitting $26.32. 54,560,140 shares of the company's stock were exchanged, compared to its average volume of 38,186,812. The business has a 50-day moving average price of $26.30 and a two-hundred day moving average price of $27.41. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $149.14 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The company's revenue for the quarter was up 24.7% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's payout ratio is 121.99%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Guggenheim restated a "buy" rating and set a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Finally, Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.